Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_assertion type Assertion NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_head.
- NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_assertion description "[Although anti-CD19 CAR T cells are at an early stage of development, the potent antigen-specific activity observed in patients suggests that infusions of anti-CD19 CAR T cells might become a standard therapy for some B-cell malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_provenance.
- NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_assertion evidence source_evidence_literature NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_provenance.
- NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_assertion SIO_000772 23546520 NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_provenance.
- NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_assertion wasDerivedFrom befree-20150227 NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_provenance.
- NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_assertion wasGeneratedBy ECO_0000203 NP252542.RAd2vqnRmCcFSvSYTk-FVSofRMVKtZIi2o1uTGCwXWsLA130_provenance.